[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650212":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":31,"collaborators":26,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":26,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":26,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":26,"overallStatus":55,"whyStopped":26,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":26},{"fullName":5,"class":6},"University of Health Sciences Lahore","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group-I: Aspirin Group","EXPERIMENTAL","Participants receive low-dose aspirin (75 mg once daily orally) starting from 8-16 weeks of gestation up to 36 weeks of gestation or until delivery, along with standard care (progesterone and cervical cerclage if indicated)",[13],"Drug: Low-dose Aspirin",{"label":15,"type":16,"description":17,"interventionNames":18},"Group-II: Placebo Group","PLACEBO_COMPARATOR","Participants receive a daily matching oral placebo starting from 8-16 weeks of gestation up to 36 weeks of gestation or until delivery, along with standard care (per-rectal progesterone and cervical cerclage if needed)",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Low-dose Aspirin","Participants take low-dose aspirin 75 mg orally once daily starting from 8-16 weeks of gestation until 36 weeks of gestation or delivery (whichever comes first), alongside routine clinical care (progesterone and cervical cerclage if indicated).",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Participants take a daily matching oral placebo tablet starting from 8-16 weeks of gestation until 36 weeks of gestation or delivery, alongside routine clinical care (per-rectal progesterone and cervical cerclage if indicated).",[15],{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Rida Tariq","Principle Investigator","100650212","low-dose-aspirin-vs-placebo-in-prevention-of-recurrent-spontaneous-preterm-labour-100650212",false,"NCT07745595","Low Dose Aspirin vs Placebo in Prevention of Recurrent Spontaneous Preterm Labour","Comparison of Low Dose Aspirin vs Placebo in the Prevention of Recurrent Spontaneous Preterm Labou","Inclusion Criteria:\n\n1. Age \\> 18 years.\n2. Singleton alive pregnancy.\n3. History of spontaneous preterm birth (22 to 37 weeks of gestation).\n4. Hemoglobin (Hb) \\> 10 g\u002FdL.\n5. Absence of fetal anomalies on ultrasound examination.\n\nExclusion Criteria:\n\n1. Primigravida.\n2. Multiple pregnancy.\n3. Maternal age \\> 40 years.\n4. Known history of allergy or hypersensitivity to aspirin.\n5. Known maternal comorbidities including Pregnancy-Induced Hypertension (PIH), Gestational Diabetes Mellitus (GDM), cardiac disease, HELLP syndrome, thrombocytopenia, thrombocytopathy, or epilepsy.\n6. Presence of a cervical cerclage prior to study enrollment.","FEMALE","18 Years","40 Years",{"count":46,"type":47},162,"ESTIMATED","INTERVENTIONAL",[50],"NA","Preterm birth-defined as delivery before 37 weeks of gestation-is a leading cause of neonatal morbidity and mortality worldwide, particularly in resource-limited settings. Women with a history of spontaneous preterm birth face a significantly higher risk of experiencing premature labor in subsequent pregnancies. Impaired uteroplacental blood flow, inflammation, and abnormal clot formation are key contributing factors to spontaneous preterm delivery.\n\nLow-dose aspirin is an affordable, widely available medication that exerts anti-inflammatory and antithrombotic effects by inhibiting platelet aggregation and prostaglandin synthesis. This study aims to evaluate whether low-dose aspirin (75 mg daily), initiated between 8 and 16 weeks of gestation, can effectively reduce the incidence of recurrent spontaneous preterm labor in pregnant women with a prior history of premature delivery compared to a placebo. Participants will be monitored throughout their pregnancy up to 36 weeks or delivery to evaluate gestational age at birth and labor outcomes.",[53,54],"Preterm Labor","Premature Birth","NOT_YET_RECRUITING","2026-08-07",{"date":58,"type":59},"2026-08-12","ACTUAL",{"date":61,"type":47},"2026-08-20",{"date":63,"type":47},"2027-08-15",{"name":5,"class":6}]